News coverage about Protagonist Therapeutics (NASDAQ:PTGX) has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Protagonist Therapeutics earned a daily sentiment score of 0.08 on Accern’s scale. Accern also assigned news stories about the company an impact score of 42.8486743103424 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Shares of Protagonist Therapeutics stock traded down $0.18 on Friday, hitting $8.90. 113,896 shares of the company traded hands, compared to its average volume of 213,032. The stock has a market cap of $188.67, a P/E ratio of -4.28 and a beta of 3.56. Protagonist Therapeutics has a 12-month low of $7.85 and a 12-month high of $23.97.
Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings data on Wednesday, March 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.34) by $0.19. The business had revenue of $11.28 million during the quarter, compared to the consensus estimate of $8.75 million. research analysts anticipate that Protagonist Therapeutics will post -0.66 earnings per share for the current year.
Several equities analysts have recently commented on PTGX shares. BidaskClub upgraded shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, December 29th. Zacks Investment Research cut shares of Protagonist Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 4th. Stifel Nicolaus started coverage on shares of Protagonist Therapeutics in a report on Monday, January 29th. They set a “buy” rating and a $32.00 price target on the stock. Finally, BMO Capital Markets restated an “outperform” rating and set a $42.00 price target (down from $44.00) on shares of Protagonist Therapeutics in a report on Thursday, March 8th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $26.75.
In related news, insider David Y. Liu sold 3,500 shares of the company’s stock in a transaction on Monday, March 12th. The shares were sold at an average price of $21.29, for a total value of $74,515.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder X L.P. Canaan sold 1,204 shares of the company’s stock in a transaction on Tuesday, March 13th. The stock was sold at an average price of $20.84, for a total transaction of $25,091.36. The disclosure for this sale can be found here. Insiders sold 79,492 shares of company stock valued at $1,639,355 over the last quarter. 15.50% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Protagonist Therapeutics (PTGX) Stock Price” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/04/13/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-protagonist-therapeutics-ptgx-stock-price.html.
Protagonist Therapeutics Company Profile
Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.